In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Juno and MedImmune enter non-Hodgkin's lymphoma clinical trial collaboration

Executive Summary

Juno Therapeutics Inc. and MedImmune LLC will work together on a clinical trial evaluating the combination of one of Juno's CD19-direted chimeric antigen receptor (CAR) T-cell candidates together with MedImmune's PD-L1 inhibitor durvalumab (MEDI4736). The study will focus on safety and efficacy of the combination as a treatment for non-Hodgkin's lymphoma.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Trial Collaborations
    • R&D (No Licensing)

Related Companies